Der var ingen klinisk relevante ændringer i smertescore i forhold til baseline for hverken patienter behandlet med methylnaltrexonbromid eller patienter behandlet med placebo.
There were no clinically relevant changes in pain scores from baseline in either the methylnaltrexone bromide or placebo-treated patients.